UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): October 21, 2009
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE
|
On
October 20, 2009, Oramed Pharmaceuticals Inc. issued a press release announcing
that its poster entitled “A novel GLP-1 analog delivered orally reduces
postprandial glucose excursions in a porcine model,” has been accepted for
presentation at the Diabetes Technology Society’s Ninth Annual Meeting in San
Francisco, California between November 5-7, 2009.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.1
and is incorporated by reference herein.
|
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
(d)
|
Exhibits
|
|
Exhibit
Number
|
Description
|
||||
|
99.1
|
Press
Release dated October 20, 2009.
|
||||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS
INC.
|
|||
|
Dated:
October 21, 2009
|
|||
|
|
By:
|
/s/
Nadav Kidron
|
|
|
Nadav
Kidron
|
|||
|
President,
CEO and Director
|
|||
Exhibit
Index
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated October 20,
2009.
|
Oramed
Pharmaceuticals was Chosen to Present Results of a GLP-1
Analog
Oral Administration Study at the Diabetes Technology Society’s
Ninth
Annual Meeting (November 5-7, 2008; San Francisco, California)
JERUSALEM,
Israel – October 20, 2009 – Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com),
a developer of oral drug delivery systems, announced today that its poster
entitled “A novel GLP-1 analog delivered orally reduces postprandial glucose
excursions in a porcine model,” has been accepted for presentation at the
Diabetes Technology Society’s Ninth Annual Meeting in San Francisco, California
between November 5-7, 2009.
“The
selection of Oramed as one of the companies to present at the Diabetes
Technology Conference is a wonderful opportunity for us to demonstrate our
technology to the world’s leading diabetes scientists,” said Nadav Kidron,
Oramed CEO.
Oramed’s
abstract will be presented on Thursday November 5, 2009, at 5:30 PM. The poster
will be available for viewing throughout the conference.
For more
information about the Diabetes Technology Society’s Ninth Annual Meeting, please
visit http://www.diabetestechnology.org/
For more
information about Oramed Pharmaceuticals, please visit www.oramed.com
About
Oramed Pharmaceuticals
Oramed
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is
seeking to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed’s technology is based on over 25 years of
research by top research scientists at Jerusalem’s Hadassah Medical Center. The
Company’s corporate and R&D headquarters are based in
Jerusalem.
For more
information, please visit www.oramed.com
Forward-looking
statements
Some of the statements contained in
this press release are forward-looking statements which involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from other
pharmaceutical or biotechnology companies; and the company’s ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to the company’s filings with the
Securities and Exchange Commission for a comprehensive list of risk factors that
could cause actual results, performance or achievements of the company to differ
materially from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any forward-looking
statements.
Company
Contact:
Oramed
Pharmaceuticals
Tara
Horn
Cell: +
972-54-334-318
Office: +
972-2-566-0001
Email:
tara@oramed.com